The extrapulmonary effects of increasing doses of formoterol in patients with asthma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-04

AUTHORS

C. D. Burgess, M. Ayson, S. Rajasingham, J. Crane, G. Della Cioppa, M. D. Till

ABSTRACT

Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96 μg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9 h following each dose. Results: There was no difference between the maximum effects of formoterol 12 μg and placebo; the 24 μg dose significantly decreased plasma K (−0.2 mmol · l−1) and increased blood glucose (1.8 mmol · l−1) compared to placebo. The two highest doses affected most of the variables with the 96 μg dose being significantly different from placebo for all indices, heart rate (9 beats · min−1), systol BP (4 mmHg), diastolic BP (−3 mmHg), QS2I (−11 ms), QTc (17 ms), plasma K (−0.5 mmol · l−1) and blood glucose (2.6 mmol · l−1). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance. More... »

PAGES

141-147

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050435

DOI

http://dx.doi.org/10.1007/s002280050435

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050389605

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9626918


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchodilator Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Formoterol Fumarate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemodynamics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Potassium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burgess", 
        "givenName": "C. D.", 
        "id": "sg:person.01334442376.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334442376.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ayson", 
        "givenName": "M.", 
        "id": "sg:person.0612257664.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612257664.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rajasingham", 
        "givenName": "S.", 
        "id": "sg:person.0660373064.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660373064.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crane", 
        "givenName": "J.", 
        "id": "sg:person.0625622631.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625622631.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ciba-Geigy Ltd, Basel, Switzerland, CH", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Ciba-Geigy Ltd, Basel, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Della Cioppa", 
        "givenName": "G.", 
        "id": "sg:person.0652147271.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652147271.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ciba-Geigy Ltd, Basel, Switzerland, CH", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Ciba-Geigy Ltd, Basel, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Till", 
        "givenName": "M. D.", 
        "id": "sg:person.01163017140.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163017140.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00615959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002416913", 
          "https://doi.org/10.1007/bf00615959"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-04", 
    "datePublishedReg": "1998-04-01", 
    "description": "Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96\u2009\u03bcg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9\u2009h following each dose. Results: There was no difference between the maximum effects of formoterol 12\u2009\u03bcg and placebo; the 24\u2009\u03bcg dose significantly decreased plasma K (\u22120.2\u2009mmol\u200a\u00b7\u200al\u22121) and increased blood glucose (1.8\u2009mmol\u200a\u00b7\u200al\u22121) compared to placebo. The two highest doses affected most of the variables with the 96\u2009\u03bcg dose being significantly different from placebo for all indices, heart rate (9\u2009beats\u200a\u00b7\u200amin\u22121), systol BP (4\u2009mmHg), diastolic BP (\u22123\u2009mmHg), QS2I (\u221211\u2009ms), QTc (17\u2009ms), plasma K (\u22120.5\u2009mmol\u200a\u00b7\u200al\u22121) and blood glucose (2.6\u2009mmol\u200a\u00b7\u200al\u22121). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002280050435", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "54"
      }
    ], 
    "keywords": [
      "doses of formoterol", 
      "blood glucose", 
      "heart rate", 
      "plasma K", 
      "double-blind design", 
      "dry powder inhaler", 
      "electrocardiographic QTc interval", 
      "dose-dependent effect", 
      "formoterol 12", 
      "moderate asthma", 
      "extrapulmonary effects", 
      "blood pressure", 
      "electromechanical systole", 
      "diastolic BP", 
      "QTc interval", 
      "plasma potassium", 
      "clinical significance", 
      "powder inhaler", 
      "high dose", 
      "placebo", 
      "formoterol", 
      "high doses", 
      "separate days", 
      "doses", 
      "metabolic response", 
      "dose", 
      "FEV1", 
      "asthma", 
      "patients", 
      "maximum effect", 
      "glucose", 
      "QS2I", 
      "QTc", 
      "inhaler", 
      "systole", 
      "effect", 
      "days", 
      "rate", 
      "response", 
      "interval", 
      "index", 
      "differences", 
      "significance", 
      "potassium", 
      "BP", 
      "pressure", 
      "variables", 
      "measurements", 
      "design"
    ], 
    "name": "The extrapulmonary effects of increasing doses of formoterol in patients with asthma", 
    "pagination": "141-147", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050389605"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050435"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9626918"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050435", 
      "https://app.dimensions.ai/details/publication/pub.1050389605"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_270.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002280050435"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      21 PREDICATES      95 URIs      86 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050435 schema:about N380d5d0148514d79a8e5149980426381
2 N5c94479a88ed4ad0a5f6696c386f1fdb
3 N607c16ca308644b68176c54c2c90c483
4 N784729b3ec5043989e449e29c1a45122
5 N88bcc8b21d8640109fd6d6a89b286019
6 N8d2f931836b143c7a45ec13c8d1fd9f6
7 N92d5fa5e75144527b18d304f33366ea0
8 N9d05ea5b0518425ebff740fd99d5da46
9 Na87560d5a57a4b78bd9b65096aa485e0
10 Na975f49b268c456a940003d5d6c69a86
11 Nae9c708bf29d4e9ab6f1e66a3413da16
12 Nb722ee7d01794907b71faeddf8af3bd6
13 Nbc3bba61207744f3a23782972b41a87b
14 Ncc37ad4ca2e4426bb5b01cc7633b6e03
15 Nd6dcade988ef42d0b34332d97717cfbb
16 Nd7aef2ca4f364223980200ef9279f79f
17 Ndb3e90d45ca24a1a826868ca578821b9
18 Ne582f8bb4df546999bd0b248a389604a
19 Nfaf9657df2334861b274e609990aab06
20 anzsrc-for:11
21 anzsrc-for:1102
22 schema:author N5b0793d410f54cd59522cae6a656e91d
23 schema:citation sg:pub.10.1007/bf00615959
24 schema:datePublished 1998-04
25 schema:datePublishedReg 1998-04-01
26 schema:description Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96 μg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9 h following each dose. Results: There was no difference between the maximum effects of formoterol 12 μg and placebo; the 24 μg dose significantly decreased plasma K (−0.2 mmol · l−1) and increased blood glucose (1.8 mmol · l−1) compared to placebo. The two highest doses affected most of the variables with the 96 μg dose being significantly different from placebo for all indices, heart rate (9 beats · min−1), systol BP (4 mmHg), diastolic BP (−3 mmHg), QS2I (−11 ms), QTc (17 ms), plasma K (−0.5 mmol · l−1) and blood glucose (2.6 mmol · l−1). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N25b49c9697ab42288596809ec0d3734e
30 Na8977158f93d40258fe025307643991b
31 sg:journal.1054337
32 schema:keywords BP
33 FEV1
34 QS2I
35 QTc
36 QTc interval
37 asthma
38 blood glucose
39 blood pressure
40 clinical significance
41 days
42 design
43 diastolic BP
44 differences
45 dose
46 dose-dependent effect
47 doses
48 doses of formoterol
49 double-blind design
50 dry powder inhaler
51 effect
52 electrocardiographic QTc interval
53 electromechanical systole
54 extrapulmonary effects
55 formoterol
56 formoterol 12
57 glucose
58 heart rate
59 high dose
60 high doses
61 index
62 inhaler
63 interval
64 maximum effect
65 measurements
66 metabolic response
67 moderate asthma
68 patients
69 placebo
70 plasma K
71 plasma potassium
72 potassium
73 powder inhaler
74 pressure
75 rate
76 response
77 separate days
78 significance
79 systole
80 variables
81 schema:name The extrapulmonary effects of increasing doses of formoterol in patients with asthma
82 schema:pagination 141-147
83 schema:productId Nb72ee0314cef4e08b4882820b7ae93f9
84 Nd3efc4b0ca8a41738f559e9b752db202
85 Nfdddadc7350e4cc7a4b064a9211ddf01
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050389605
87 https://doi.org/10.1007/s002280050435
88 schema:sdDatePublished 2022-09-02T15:48
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher Na288c98bf7c64293842391b78d603a5b
91 schema:url https://doi.org/10.1007/s002280050435
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N0e269c27376743fdb4f0e3c359aae064 rdf:first sg:person.0660373064.00
96 rdf:rest N7ce59fe5249d427189cfaa73a7738147
97 N25b49c9697ab42288596809ec0d3734e schema:volumeNumber 54
98 rdf:type schema:PublicationVolume
99 N2ef58b17aaec45f98939c5f153f535f8 rdf:first sg:person.01163017140.29
100 rdf:rest rdf:nil
101 N380d5d0148514d79a8e5149980426381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Asthma
103 rdf:type schema:DefinedTerm
104 N5b0793d410f54cd59522cae6a656e91d rdf:first sg:person.01334442376.07
105 rdf:rest Nbaa3e787054f43cdad61af3798c21cd3
106 N5c94479a88ed4ad0a5f6696c386f1fdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Ethanolamines
108 rdf:type schema:DefinedTerm
109 N607c16ca308644b68176c54c2c90c483 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Adrenergic beta-Agonists
111 rdf:type schema:DefinedTerm
112 N784729b3ec5043989e449e29c1a45122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Cross-Over Studies
114 rdf:type schema:DefinedTerm
115 N7ce59fe5249d427189cfaa73a7738147 rdf:first sg:person.0625622631.63
116 rdf:rest N7fb3cc48a198471588af69c3f892b2d7
117 N7fb3cc48a198471588af69c3f892b2d7 rdf:first sg:person.0652147271.70
118 rdf:rest N2ef58b17aaec45f98939c5f153f535f8
119 N88bcc8b21d8640109fd6d6a89b286019 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Formoterol Fumarate
121 rdf:type schema:DefinedTerm
122 N8d2f931836b143c7a45ec13c8d1fd9f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Bronchodilator Agents
124 rdf:type schema:DefinedTerm
125 N92d5fa5e75144527b18d304f33366ea0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Middle Aged
127 rdf:type schema:DefinedTerm
128 N9d05ea5b0518425ebff740fd99d5da46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Female
130 rdf:type schema:DefinedTerm
131 Na288c98bf7c64293842391b78d603a5b schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Na87560d5a57a4b78bd9b65096aa485e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Drug Administration Schedule
135 rdf:type schema:DefinedTerm
136 Na8977158f93d40258fe025307643991b schema:issueNumber 2
137 rdf:type schema:PublicationIssue
138 Na975f49b268c456a940003d5d6c69a86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Male
140 rdf:type schema:DefinedTerm
141 Nae9c708bf29d4e9ab6f1e66a3413da16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Dose-Response Relationship, Drug
143 rdf:type schema:DefinedTerm
144 Nb722ee7d01794907b71faeddf8af3bd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 Nb72ee0314cef4e08b4882820b7ae93f9 schema:name doi
148 schema:value 10.1007/s002280050435
149 rdf:type schema:PropertyValue
150 Nbaa3e787054f43cdad61af3798c21cd3 rdf:first sg:person.0612257664.28
151 rdf:rest N0e269c27376743fdb4f0e3c359aae064
152 Nbc3bba61207744f3a23782972b41a87b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Adult
154 rdf:type schema:DefinedTerm
155 Ncc37ad4ca2e4426bb5b01cc7633b6e03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Time Factors
157 rdf:type schema:DefinedTerm
158 Nd3efc4b0ca8a41738f559e9b752db202 schema:name pubmed_id
159 schema:value 9626918
160 rdf:type schema:PropertyValue
161 Nd6dcade988ef42d0b34332d97717cfbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Hemodynamics
163 rdf:type schema:DefinedTerm
164 Nd7aef2ca4f364223980200ef9279f79f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Blood Glucose
166 rdf:type schema:DefinedTerm
167 Ndb3e90d45ca24a1a826868ca578821b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Administration, Inhalation
169 rdf:type schema:DefinedTerm
170 Ne582f8bb4df546999bd0b248a389604a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Potassium
172 rdf:type schema:DefinedTerm
173 Nfaf9657df2334861b274e609990aab06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Double-Blind Method
175 rdf:type schema:DefinedTerm
176 Nfdddadc7350e4cc7a4b064a9211ddf01 schema:name dimensions_id
177 schema:value pub.1050389605
178 rdf:type schema:PropertyValue
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
183 schema:name Cardiorespiratory Medicine and Haematology
184 rdf:type schema:DefinedTerm
185 sg:journal.1054337 schema:issn 0031-6970
186 1432-1041
187 schema:name European Journal of Clinical Pharmacology
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01163017140.29 schema:affiliation grid-institutes:grid.419481.1
191 schema:familyName Till
192 schema:givenName M. D.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163017140.29
194 rdf:type schema:Person
195 sg:person.01334442376.07 schema:affiliation grid-institutes:grid.29980.3a
196 schema:familyName Burgess
197 schema:givenName C. D.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334442376.07
199 rdf:type schema:Person
200 sg:person.0612257664.28 schema:affiliation grid-institutes:grid.29980.3a
201 schema:familyName Ayson
202 schema:givenName M.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612257664.28
204 rdf:type schema:Person
205 sg:person.0625622631.63 schema:affiliation grid-institutes:grid.29980.3a
206 schema:familyName Crane
207 schema:givenName J.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625622631.63
209 rdf:type schema:Person
210 sg:person.0652147271.70 schema:affiliation grid-institutes:grid.419481.1
211 schema:familyName Della Cioppa
212 schema:givenName G.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652147271.70
214 rdf:type schema:Person
215 sg:person.0660373064.00 schema:affiliation grid-institutes:grid.29980.3a
216 schema:familyName Rajasingham
217 schema:givenName S.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660373064.00
219 rdf:type schema:Person
220 sg:pub.10.1007/bf00615959 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002416913
221 https://doi.org/10.1007/bf00615959
222 rdf:type schema:CreativeWork
223 grid-institutes:grid.29980.3a schema:alternateName Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ
224 schema:name Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ
225 rdf:type schema:Organization
226 grid-institutes:grid.419481.1 schema:alternateName Ciba-Geigy Ltd, Basel, Switzerland, CH
227 schema:name Ciba-Geigy Ltd, Basel, Switzerland, CH
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...